Cara Therapeutics Gets Price Targets Cuts By Analysts After Weak Q4 Results

Cara Therapeutics, Inc. CARA posted downbeat Q4 results.

Cara Therapeutics posted a Q4 loss of $0.56 per share, versus market expectations of $0.32 per share. The company’s quarterly sales came in at $3.26 million, versus estimates of $16.25 million.

Cara Therapeutics shares dropped 29.6% to $7.05 in pre-market trading.

These analysts made changes to their price targets on Cara Therapeutics following the release of results.

  • HC Wainwright & Co. cut the price target on Cara Therapeutics from $25 to $20. HC Wainwright & Co. analyst Oren Livnat maintained a Buy rating.
  • Piper Sandler slashed the price target on Cara Therapeutics from $25 to $13. Piper Sandler analyst David Amsellem maintained an Overweight rating.
  • Needham lowered the price target on Cara Therapeutics from $26 to $22. Needham analyst Joseph Stringer maintained the stock with a Buy.

Read More: $1M Bet On Domino's Pizza? Check Out These 4 Stocks Insiders Are Buying

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetSmall CapPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!